FIGURE 66. Proportion of cohort pre-institutionalised over time with model fit by MMSE (a), Barthel ADL Index (b) and age (c) all at the start of the study.

FIGURE 66Proportion of cohort pre-institutionalised over time with model fit by MMSE (a), Barthel ADL Index (b) and age (c) all at the start of the study

(a) Lower curve MMSE = 10, middle curve MMSE = 14.5 (mean), upper curve MMSE = 20; (b) lower curve Barthel ADL Index = 10, middle curve Barthel ADL Index = 17 (mean), upper curve Barthel ADL Index = 20; (c) lower curve age = 85 years, middle curve age = 78 years (mean), upper curve age = 70 years.

From: 6, The Peninsula Technology Assessment Group cost–utility assessment

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.